Oncology Practice Associate Editor Hope S. Rugo, MD, reveals several anticipated studies from the 40th annual San Antonio Breast Cancer Symposium, set to begin on Wednesday, Dec. 6:
• GS4-02. Randomized comparison of adjuvant aromatase inhibitor exemestane (E) plus ovarian function suppression (OFS) vs. tamoxifen (T) plus OFS in premenopausal women with hormone receptor positive (HR+) early breast cancer (BC): Update of the combined TEXT and SOFT trials.
• GS2-07. MANTA – A randomized phase 2 study of fulvestrant in combination with the dual mTOR inhibitor AZD2014 or everolimus or fulvestrant alone in estrogen receptor-positive advanced or metastatic breast cancer. Dr. Hope S. Rugo
• GS3-01. A prospective randomized multicenter phase 3 trial of additional 2 versus additional 5 years of anastrozole after initial 5 years of adjuvant endocrine therapy – results from 3,484 postmenopausal women in the ABCSG-16 trial.
• GS4-07. Results from a randomized placebo-controlled phase 2 trial evaluating exemestane ± enzalutamide in patients with hormone receptor–positive breast cancer.
• GS6-07. EMBRACA: A phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physician’s choice of therapy in patients with advanced breast cancer and a germline BRCA mutation.
• GS6-03. Circulating tumor cells (CTCs) 5 years after diagnosis are prognostic for late recurrence in operable stage II-III breast cancer.
• GS3-08. Pathological complete response predicts event-free and distant disease-free survival in the I-SPY2 TRIAL.
• P5-21-25. Efficacy and safety of palbociclib (PAL) + letrozole (LET) as first-line therapy in estrogen receptor positive (ER+)/human epidermal growth factor receptor 2 negative (HER2) advanced breast cancer (ABC): Findings by geographic region from PALOMA-2.
Dr. Rugo is professor of medicine, University of California, San Francisco, and director, breast oncology and clinical trials education, UCSF Helen Diller Family Comprehensive Cancer Center.